Skip to main content

Ocriplasmin ophthalmic Side Effects

Medically reviewed by Last updated on Oct 4, 2023.

Applies to ocriplasmin ophthalmic: parenteral injection.

Side effects include:

Vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema.

For Healthcare Professionals

Applies to ocriplasmin ophthalmic: intravitreal solution.


The most commonly reported side effects included vitreous floaters, eye pain, photopsia, and blurred vision.[Ref]


Very common (10% or more): Vitreous floaters (up to 16.8%), macular hole (up to 15.8%), eye pain (up to 13.1%), photopsia (up to 11.8%), chromatopsia, conjunctival hemorrhage

Common (1% to 10%): Abnormal optical coherence tomography (OCT), anterior chamber cell, anterior chamber flare, blurred vision, conjunctival edema, conjunctival hyperemia, cystoid macular edema, decreased best corrected visual acuity (BCVA), dry eye, dyschromatopsia, eye irritation, eye pruritus, eyelid edema, foreign body sensation in eyes, increased intraocular pressure, increased lacrimation, iritis, macular degeneration, macular edema, metamorphopsia, ocular discomfort, ocular hyperemia, photophobia, photopsia, reduced visual acuity, retinal breaks, retinal degeneration, retinal edema, retinal hemorrhage, retinal pigment epitheliopathy, subretinal fluid, visual impairment, vitreous detachment, vitreous hemorrhage, vitritis

Uncommon (0.1% to 1%): Anterior chamber inflammation, conjunctival irritation, corneal abrasion, diplopia, eye inflammation, hyphema, lens subluxation, miosis, night blindness, retinal detachment, retinal tear, serious acute visual impairment, severe acute visual impairment, transient blindness, unequal pupils

Frequency not reported: Dim vision, macular hole progression

Postmarketing reports: Impaired pupillary reflex[Ref]

Nervous system

Very common (10% or more): Abnormal color vision test, abnormal retinogram

Common (1% to 10%): Abnormal macular reflex, increased intraocular pressure, visual field defect, visual symptoms perceived in the contralateral eye

Frequency not reported: Scotoma[Ref]


Common (1% to 10%): Intravitreal injection procedure associated effects[Ref]


Frequency not reported: Immunogenicity[Ref]

More about ocriplasmin ophthalmic

Patient resources

Other brands


Professional resources

Other brands


Related treatment guides


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Jetrea (ocriplasmin ophthalmic). ThromboGenics Inc. 2012.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.